Sosei Group renamed Nxera Pharma
The pharma company known as Sosei Group (TYO 4565) or Sosei Heptares will now go by the name Nxera Pharma.
Subsidiaries of the Japanese group—Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea—will all go under the Nxera brand.
"Determination to lead the next era of medicine"Chris Cargill, president and chief executive of Nxera, said: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our company’s journey. It follows the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, including Heptares Therapeutics in 2015 and the Idorsia Pharmaceuticals Japan and Korea businesses in 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze